Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia

BACKGROUND: To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 × 10(10) viral particles per 0.5 mL dose), we conducted a single-dose, randomised, double-blind, placebo-controlled, parallel gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lioznov, Dmitry, Amosova, Irina, Sheetikov, Savely A., Zornikova, Ksenia V., Serdyuk, Yana, Efimov, Grigory A., Tsyferov, Mikhail, Khmelevskii, Mikhail, Afanasiev, Andrei, Khomyakova, Nadezhda, Zubkov, Dmitry, Tikhonov, Anton, Zhu, Tao, Barreto, Luis, Dzutseva, Vitalina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994755/
https://www.ncbi.nlm.nih.gov/pubmed/36888640
http://dx.doi.org/10.1371/journal.pone.0278878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994755/
https://www.ncbi.nlm.nih.gov/pubmed/36888640
http://dx.doi.org/10.1371/journal.pone.0278878

Ejemplares similares